N-methyl-D-aspartate antagonists and neuropathic pain: The search for relief

Journal of Medicinal Chemistry

Volumn 50, Issue 11, 2007, Pages 2557-2562

  Childers Jr , Wayne E ^a   Baudy, Reinhardt B ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; GLUTAMATE RECEPTOR; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ALLODYNIA; ANALGESIA; CENTRAL NERVOUS SYSTEM; DEPOLARIZATION; HUMAN; HYPERALGESIA; MEMBRANE POTENTIAL; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BINDING SITES; GLYCINE; HUMANS; ION CHANNEL GATING; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEIN SUBUNITS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 34250158705     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060728b     Document Type: Review

References (55)

1. Yaksh, T. L.; Sorkin, L. S. Mechanisms of neuropathic pain. Curr. Med. Chem.: Cent. Nerv. Syst. Agents 2005, 11, 2977-2994.
2. Borsook, D.; Ploghaus, A. Becerra, L. Utilizing brain imaging for analgesic drug development. Cur. Opin. Invest. Drugs 2003, 3, 1342-1347 and references therein.
3. Price, D. D. Psychological and neural mechanisms of the affective dimension of pain. Science 2000, 288, 1769-1772.
4. Petrenko, A. B.; Yamakura, T.; Baba, H.; Simoji, K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth. Analg. 2003, 97, 1108-1116.
5. Sindrup, S. H.; Jensen, T. S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83, 389-400.
6. Chizh, B. A.; Headley, P. M. NMDA antagonists and neuropathic pain - multiple drug targets and multiple uses. Cur. Pharm. Des. 2005, 11, 2977-2994.
7. Salter, M. W. Cellular signalling pathways of spinal pain neuroplasticity as targets for analgesic development. Cur. Top. Med. Chem. 2005, 5, 557-567.
8. Yu, X.-M.; Salter, M. W. Src, a molecular switch governing control of synaptic transmission mediated by N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 7697-7704.
9. Davies, S. N.; Lodge, D. Evidence for involvement of N- methylaspartate receptors in "windup" of class 2 neurones in the dorsal horn of the rat. Brain Res. 1987, 424, 402-406.
10. Dickenson, A. H.; Sullivan, A. F. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987, 26, 1235-1238.
11. Carlton, S. M. Peripheral excitatory amino acids. Curr. Opin. Pharamcol. 2001, 1, 52-56 and references therein.
12. Parsons, C. G.; Danysz, W.; Quack, G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 1998, 11, 523-569.
13. Furukawa, H.; Singh, S. K.; Mancusso, R.; Gouaux, E. Subunit arrangement and function in NMDA receptors. Nature 2005, 438, 185-192.
14. Malenka, R. C.; Bear, M. F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44, 5-21.
15. Laube, B.; Kuhse, J.; Betz, H. Evidence for a tetrameric structure of recombinant NMDA receptors. J. Neurosci. 1998, 18, 2954-2961.
16. Sucher, N. J.; Akbarian, S.; Chi, C. L.; Leclerc, C. L.; Awobuluyi, M.; et al. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J. Neurosci. 1995, 15, 6509-6520.
17. Gogas, K. R. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. 2006, 6, 68-74 and references therein.
18. For a recent review, see the following: Brown, D. G.; Krupp, J. J. N-Methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr. Top. Med. Chem. 2006, 6, 749-770.
19. Hoyte, L.; Barber, P. A.; Buchan, A. M.; Hill, M. D. The rise and fall of NMDA antagonists for ischemic stroke. Curr. Mol. Med. 2004, 4, 131-136.
20. Kristensen, J. D.; Svensson, B.; Gordh, T., Jr. The NMDA-receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans. Pain 1992, 51, 249-253.
21. Childers, W. E., Jr.; Abou-Gharbia, M. A.; Moyer, J. A.; Zaleska, M. M. EAA-090: neuroprotectant competitive NMDA antagonist. Drugs Future 2002, 27, 633-638.
22. Sun, L.; Chiu, D.; Kowal, D.; Simon, R.; Smeyne, M.; et al. Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-[8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl]-ethyl-phosphonic acid) and EAB-318 (R-α-amino-5-chloro-1-(phosphonomethyl)- 1H-benzimidazole-2-propanoic acid hydrochloride). J. Pharmacol. Exp. Ther. 2004, 310, 563-570.
23. Brandt, M. R.; Cummons, T. A.; Potestio, L.; Sukoff, S. J.; Rosenzweig-Lipson, S. Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel (EAA-090; 2-[8,9-dioxo-2,6-diazabicyclo[5.2.0]- non-1(7)-en-2-yl]-ethyl]phosphonic acid) on chemically induced thermal hypersensitivity. J. Pharmacol. Exp. Ther. 2005, 313, 1379-1386.
24. Baudy, R. B.; Butera, J. A.; Sze, J.; Chen, H.; Jain, U.; et al. Derivatives To Improve the Oral Bioavailability and Brain Levels of [2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic Acid (EAA-090, perzinfotel), a Competitive NMDA Antagonist. Presented at the 230th National Meeting of the American Chemical Society; Washington, DC, August 28-September 1, 2005.
25. Baudy, R. B.; Chen, H.; Jain, U.; Huselton, C.; Mugford, C.; et al. Pharmacokinetic and Pharmacodynamic Effects of an Oxymethylene-spaced Diphenylester Derivative of Perzinfotel (EAA-090; [2-(8,9-Dioxo-2,6- diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic Acid) in Inflammatory and Neuropathic Pain Models. Presented at the 230th National Meeting of the American Chemical Society; Washington, DC, August 28-September 1, 2005.
26. Mathisen, L. C.; Skjelbred, P.; Skoglund, L. A.; Oeyer, I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofcial pain. Pain 1995, 61, 215-220.
27. Hocking, G.; Cousins, M. J. Ketamine in chronic pain management: an evidence-based review. Anesth. Analg. 2003, 97, 1730-1739.
28. Smith, P. A. Neuropathic pain: drug targets for current and future inverventions. Drug News Perspect. 2004, 17, 5-17.
29. Leung, A.; Wallace, M. S.; Ridgeway, B.; Yaksh, T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001, 91, 177-187.
30. McQuay, H. J.; Carroll, D.; Jadad, A. R.; Glynn, C. J.; Jack, T.; et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994, 59, 127-133.
31. Nelson, K. A.; Park, K. M.; Robinovitz, E.; Tsigos, C.; Max, M. B. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic nerualgia. Neurology 1997, 48, 1212-1218.
32. Pud, D.; Eisenberg, E.; Spitzer, A.; Rivka, A.; Fried, G.; et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 1998, 75, 349-354.
33. Wiech, K.; Kiefer, R.-T.; Toepfner, S.; Preissi, J.; Braun, C.; et al. A placebo-controlled randomized crossover trial of the N-methyl-D- aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth. Analg. 2004, 98, 408-413.
34. Sang, C. N.; Booher, S.; Gilron, I.; Parada, S. I.; Max, M. B. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002, 96, 1053-1061.
35. Eisenberg, E.; Kleiser, A.; Dortort, A.; Haim, T.; Yarnitsky, D. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur. J. Pain 1998, 2, 321-327.
36. DOV Pharmaceutical, Inc. Announces Results of Phase III Trial Analysis for Bicifadine, May 22, 2006. DOV Press Releases. http://www.dovpharm.com.
37. CeNeS Announces Successful Results from Its Phase IIa Clinical Trial of CNS 5161 in Neuropathic Pain, June 8, 2005. CeNeS News Archives. http://www.cenes.com.
38. Parsons, C. G.; Danysz, C. G.; Bartmann, A.; Spielmanns, P.; Frankiewica, T.; et al. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependancy and fast blocking kinetics. In vitro and in vivo characterization. Neuropharmacology 1999, 38, 85-108.
39. Christoph, T.; Reissmuller, E.; Schiene, K.; Englberger, W.; Chizh, B. A. Antiallodynic effects of NMDA glycineB antagonists in neuropathic pain: possible peripheral mechanisms. Brain Res. 2005, 1048, 218-227.
40. Wallace, M. S.; Rowbotham, M. C.; Katz, N. P.; Dworkin, R. H.; Dotson, B. S.; et al. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 2002, 59, 1694-1700.
41. Angusti, A.; Durini, E.; Vertuani, S.; Dalpiaz, A.; Ruffo, A.; et al. Synthesis and biological evaluation of pro-drugs of GW196771, a potent glycine antagonist acting at the NMDA receptor. Farmaco 2005, 60, 393-397.
42. Parsons, C. G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. 2001, 429, 71-78.
43. Sang, C. N.; Weaver, J. J.; Jinga, L.; Wouden, J. Saltarelli, M. D. The NR2B Subunit-Selective NMDA Receptor Antagonist, CP-101,606, Reduces Spontaneous Pain Intensity in Patients with Central and Peripheral Neuropathic Pain. Presented at the 33rd Annual Meeting of the Society for Neuroscience, New Orleans, LA, 2003; Abstract 814.9.
44. Wei, F.; Wang, G.-D.; Kerchner, G. A.; Kim, S. J.; Xu, H. M.; et al. Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat. Neurosci. 2001, 4, 164-169.
45. Nakazato, E.; Kato, A.; Watanabe, S. Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model. Pharmacology 2005, 73, 8-14.
46. (a) Forrest Laboratories, Inc., Press Release Archive, November 28, 2005. http://frx.com.
47. (b) Gedeon Richter and Forest Laboratories Expand Relationship with Two New Collaborations for CNS Compounds, November 29, 2005. Gedeon Richter Press Releases. http://www.richter.hu/RichterWebSite.
48. Evotec Successfully Completes Single Ascending Dose Component of Phase I Trial with EVG 101 for Alzheimer's Disease, February 3, 2006. Evotec News Releases. http://www.evotec.com.
49. King, T.; Ossipov, M. H.; Vanderah, T. W.; Porreca, F.; Lai, J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid tolerance? Neurosignals 2005, 14, 194-205.
50. Bajo, M.; Crawford, E. F.; Roberto, M.; Madamba, S. G.; Siggins, G. R. Chronic morphine treatment alters expression of N-methyl-D- aspartate receptor subunits in the extended amygdala. J. Neurosci. Res. 2006, 83, 532-537.
51. Kozela, E.; Danysz, W.; Popik, P. Uncompetitive NMDA receptor antagonists potentiate morphine antinociception recorded from the tail but not from the hind paw. Eur. J. Pharmacol. 2001, 423, 17-26.
52. Kozela, E.; Popik, P. The effects of NMDA receptor antagonists on acute morphine antinociception in mice. Amino Acids 2002, 23, 1-3.
53. Habib, A. S.; Gan, T. J. Role of analgesic adjucts in postoperative pain management. Anesth. Clin. North Am. 2005, 23, 85-107.
54. Duedahl, T. H.; Roemsing, J.; Moeiniche, S.; Dahl, J. B. A qualitative systematic review of peri-operative dextromethorphan in postoperative pain. Acta Anesth. Scand. 2006, 50, 1-13.
55. Allen, R. M.; Granger, A. L.; Dykstra, L. A. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl- deca-hydroisoquinoline-3-carboxylic acid (LY 235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the μ-opioid receptor. J. Pharmacol. Exp. Ther. 2003, 307, 785-792.